摘要
目的 探讨拉米夫定治疗肺结核合并慢性乙型肝炎患者的临床疗效.方法 选择肺结核合并慢性乙型肝炎患者98例作为研究对象,按数字表法随机分为两组,对照组49例采用常规治疗措施,观察组49例在常规治疗基础上加用拉米夫定治疗,比较两组临床疗效及不良反应.结果 治疗过程中,观察组肝功能损害率为10.20％,明显低于对照组的18.37％（x2=4.21,P＜0.05）；在治疗后,观察组的肝功能相关指标以及HBV-DNA等均明显低于对照组（t=10.72、10.11、7.68,均P＜0.05）.结论 拉米夫定治疗肺结核合并慢性乙型肝炎具有十分显著的疗效,有利于患者的早期恢复,值得临床广泛推广和应用.
Objective To evaluate the clinical efficacy of lamivudine in the treatment of pulmonary tuberculosis patients with chronic hepatitis B. Methods 98 pulmonary tuberculosis patients with chronic hepatitis B were divided into two groups. 49 patients in the control group were given conventional treatment, and 49 patients in the observation group received lamivudine Dn the basis of conventional treatment. The clinical efficacy and adverse reactions of two groups were compared. Results During treatment, the liver dysfunction rate of the observation group was 10. 20%, which was significantly lower than 18.37 % of the control group （X2 = 4.21, P 〈 0.05 ）. After treatment, the relevant indicators of liver function and HBV-DNA in the observation group were significantly lower than those in the control group （ t = 10.72,10.11,7.68, all P 〈 0.05 ）. Conclusion Lamivudine in the treatment of pulmonary tuberculosis patients with chronic hepatitis B has significant effect, which is beneficial to the patients＇ early recovery, and it is worthy of extensive promotion and application.
出处
《中国基层医药》
CAS
2013年第20期3083-3084,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
拉米夫定
结核
肺
肝炎
乙型
慢性
治疗结果
Lamivudine
Tuberculosis
pulmonary
Hepatitis B
chronic
Treatment outcome
